Precigen Inc. will participate in two upcoming virtual fireside chats to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. The first chat, hosted by Jennifer Kim of Cantor, will take place on August 27, 2025, from 11 AM to 12 PM ET. The second chat, moderated by Swayampakula Ramakanth, PhD, of H.C. Wainwright, is scheduled for September 2, 2025, from 11 AM to 12 PM ET. Participants can access the live webcasts via Precigen's website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY57629) on August 25, 2025, and is solely responsible for the information contained therein.